GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » PensionAndRetirementBenefit

CG Oncology (CG Oncology) PensionAndRetirementBenefit : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology PensionAndRetirementBenefit?

CG Oncology's PensionAndRetirementBenefit for the quarter that ended in Mar. 2024 was $0.00 Mil.


CG Oncology PensionAndRetirementBenefit Historical Data

The historical data trend for CG Oncology's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology PensionAndRetirementBenefit Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
PensionAndRetirementBenefit
- - -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
PensionAndRetirementBenefit Get a 7-Day Free Trial - - - - -

CG Oncology PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


CG Oncology (CG Oncology) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines